U.S. markets open in 2 hours 6 minutes

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.8000-0.2900 (-7.09%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.0900
Bid3.6100 x 1200
Ask0.0000 x 800
Day's Range3.7900 - 4.0200
52 Week Range1.0100 - 6.8800
Avg. Volume926,320
Market Cap106.536M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-1.5500
Earnings DateJul 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates

    Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates

    The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.

  • TheStreet.com

    Corvus Shares Surge After Positive Data From Early COVID Treatment Study

    Burlingame, California-based Corvus Pharmaceuticals said its early-stage coronavirus antibody treatment showed positive results in a Phase one trial, sending shares higher in pre-market trading.

  • Benzinga

    Looking Into Corvus Pharmaceuticals's Return On Capital Employed

    During Q2, Corvus Pharmaceuticals (NASDAQ: CRVS) brought in sales totaling $0.00. However, earnings decreased 18.86%, resulting in a loss of $10.77 million. Corvus Pharmaceuticals collected $0.00 in revenue during Q1, but reported earnings showed a $13.27 million loss.What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Corvus Pharmaceuticals's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Corvus Pharmaceuticals posted an ROCE of -0.21%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on CRVSROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Corvus Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In Corvus Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q2 Earnings Insight Corvus Pharmaceuticals reported Q2 earnings per share at $-0.36/share, which did not meet analyst predictions of $-0.28/share.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * 12 Healthcare Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.